cityslicker, I agree 100%. I'm not a doctor or biochemist but I'm a science junkie and I bought into RVX 10 years ago because it just seemed that anyone that can find and program genes to turn on or off has huge potential for so many conditions. It just seems natural.

Apabetalone, with it's good safety profile, as opposed to some pan bet inhibitors, seems well on it's way and the promising results from BoM, as well as it's sister molecules offer tremendous potential.

It is so unfortunate that financial and time pressures did not allow for the futility analysis which may have pushed the sample size up to achieving statistical significance. So close.

I do think it is unfortunate that RVX does not have the skills to position this brand for the potential it has and to tell the world about it's achievements. Don's post CiTAD presentation was basically preaching to the converted...long holders like me... and we saw the fizzle...a disaster.

I finally realized retail share holders are, in fact, important. 70% of this stock is held by the likes of Eastern Capital, Hepalink, CD Ventures, Don, Dr Wong etc therefore not in trading. Nor are many of us longs are (or were) selling. A well managed share price would have been a big help to the warrant program, a NASDAQ listing, future funding and this can only be achieved by reaching out to a much broader market of high risk investors and building awareness. There are many other markets that should be reached out to through some innovative PR activity. The good news is incredible.

This company is a gem, IMHO, because it is doing quite well in leading edge science in CVD and also, on the Zenith side promising results on mCRPC. There is so much potential but such low awareness beyond the science types.

All that being said, I am extremely frustrated by the missed opportunities but someone will get this gem and get the job done.

So thanks for your post.

GLTA

Toinv